The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron’s COVID-19 Therapy Decision Pushed, Protagonist’s Rusfertide Breakthrough Tag Update And More
Here's a roundup of top developments in the biotech space over the last 24 hours:
Protagonist Therapeutics Earns $25M Milestone Payment From Janssen Biotech
Protagonist Therapeutics (NASDAQ:PTGX) has received a $25 million milestone payment from its collaboration with Janssen Biotech Inc, a unit of Johnson & Johnson (NYSE:JNJ).…
BTIG Initiates Coverage On Protagonist Therapeutics with Buy Rating, Announces Price Target of $55
BTIG initiates coverage on Protagonist Therapeutics (NASDAQ:PTGX) with a Buy rating and announces Price Target of $55.
Protagonist Therapeutics Presented Updated Phase 2 Rusfertide Data in Polycythemia Vera at ASH 2021; Said New Phase 2 Study of Rusfertide in PV Patients With High Hematocrit Levels Demonstrated Rapid Hematocrit Control Without Need for Therapeutic Phle…
Protagonist Therapeutics (NASDAQ: PTGX) ("Protagonist" or "the Company") today presented updated data from two ongoing Phase 2 studies evaluating rusfertide in patients with polycythemia vera (PV), demonstrating its ability to essentially eliminate the need for phlebotomies in patients.
Protagonist To Go Ahead With Oral Peptide PN-235, Discontinues Phase 1 Candidate
Protagonist Therapeutics Inc (NASDAQ: PTGX) has
Protagonist Therapeutics Announces The Selection Of Oral Peptide PN-235 Into Phase 2 Clinical Development Program For Multiple Indications
Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced the selection of PN-235 (JNJ-77242113) as the final candidate for all clinical studies in multiple
Protagonist Therapeutics Offers Updated Data From Phase 2 Study Of Rusfertide In Polycythemia Vera Selected For Oral Presentations At American Society Of Hematology Dec. 11-12
Two oral presentations highlighting updated results of PV patients on rusfertide achieving hematocrit control while essentially eliminating phlebotomy
Additional abstracts to be presented at ASH, providing further
Protagonist Therapeutics Q3 EPS $(0.70) Down From $(0.21) YoY
Protagonist Therapeutics (NASDAQ:PTGX) reported quarterly losses of $(0.70) per share. This is a 233.33 percent decrease over losses of $(0.21) per share from the same period last year.
5 Short Squeeze Candidates To Watch: Progenity, Digital Brands Top List Again, SPAC AGC Joins Ahead Of Merger
Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next GameStop Corp (NYSE: GME) or AMC Entertainment Holdings Inc (NYSE: AMC).